Source https://www.fightaging.org/archives/2025/05/100-teams-in-the-xprize-healthspan-competition/
One of the challenges inherent in developing an industry of medical development aimed at the treatment of aging is that present regulatory structure and investment culture actively discourage any attempt to quantify effects on life span. While aging clocks are interesting, they cannot yet be relied upon, and no-one is willing to fund the lengthy studies needed to assess the effects of any given therapy on long term health the old-fashioned way, by waiting and watching. Aging is not yet considered a treatable medical condition by regulators, and so developers are forced by investors into optimizing their approaches to therapy for specific age-related conditions, as that is the fastest path to market.
The <a href="https://www.xprize.org/prizes/healt…
Source https://www.fightaging.org/archives/2025/05/100-teams-in-the-xprize-healthspan-competition/
One of the challenges inherent in developing an industry of medical development aimed at the treatment of aging is that present regulatory structure and investment culture actively discourage any attempt to quantify effects on life span. While aging clocks are interesting, they cannot yet be relied upon, and no-one is willing to fund the lengthy studies needed to assess the effects of any given therapy on long term health the old-fashioned way, by waiting and watching. Aging is not yet considered a treatable medical condition by regulators, and so developers are forced by investors into optimizing their approaches to therapy for specific age-related conditions, as that is the fastest path to market.
The <a href="https://www.xprize.org/prizes/healt…
What Do You Think?
comments